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1. Introduction
Epigenetic modifications stably influence gene expression without changing the underlying
DNA sequence [1]. The epigenomic era has revealed a well-connected network of molecular
processes. These processes comprise abnormal methylomes, transcriptosomes, genome-wide
histone post-transcriptional modifications patterns, histone variants, and noncoding RNAs [2].
The genome-wide DNA methylation status of cells exists in a methylated, hydroxymethylated
or unmethylated state, collectively referred to as the DNA methylome [3]. Methylation of the
DNA (DNAme) occurs in position 5 in cytosine residues. In mammals, the vast majority (98%)
of DNA methylation occurs in CpG (cytosine-phosphate-guanine) dinucleotides in somatic
cells [4]. In embryomic stem (ES) cells, however, about one-quarter of all DNA methylation
occurs in non-CpG context [4]. The haploid human genome contains approximately 29 million
CpGs, DNA methylation involves the transfer of a methyl group to cytosine in a CpG dinu‐
cleotide through DNA methyltransferases that creates or maintains methylation patterns [3].
Hydroxymethylation of cytosines has also been reported, though its biological functions are
unknown. Several methods have been developed which enable capture of genome-wide
profiling of DNA methylation. The complete DNA methylomes for several organisms are now
available, helping clarify the evolutionary story of this epigenetic mark and its distribution in
key genomic elements. The variation of DNA methylome plays an important role in regulating
normal development and differentiation. DNA methylation patterns can be inherited and
influenced by the environment, diet and aging, and disrupted in diseases [5]. From a functional
perspective, the DNA methylome variation is a stable change in a transcriptional regulatory
element, which changes the expression of a gene without any change in DNA sequence or in
the intracellular environment. However, a change in environmental conditions could perturb
the stability profile of the methylome at a locus, changing the probability of variant states
arising, even making a variant state more stable than the previous reference state [6].
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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2. Methylomes and evolution
DNA methylation is a typical characteristic of most eukaryotes and some of its features are
conserved in many species. The methylation states that present in the germline are heritable
and participate in evolution. Boffelli D and Martin DI [6] combined phylogenomic and somatic
methylation data to infer germline methylation states. Methylated CGs undergo mutation to
TG much more frequently than unmethylated CGs, but only CG decay that occurs in the
germline results in heritable sequence changes that can become fixed within a species. The
predominant trend within the genome is to lose methylated cytosines and this destrucrion of
a CpG dinucleotide by a SNP has been shown to lead to significant cis-methylation effects [7].
The loss and gain of CpGs over time is proposed to be a significant evolutionary device, the
polymorphic nature of CpG-SNP dinucleotide sequences will help define human population
epigenomics [8].
Currently, by the base-resolution sequencing, the complete methylomes for 25 organisms are
available (10 animals, 8 plants, 2 insect and 5 fungi). These eukaryotic methylomes have
provided initial insights into the evolutionary history of DNA methylation (Figure 1). Since
the density of possible methylation sites, and the distribution of 5-methyl-cytosines (5meC) is
not uniform in the genome contexts, the role of DNA methylation in promoters, gene bodies,
regulatory features, and transposable and repetitive elements can be remarkably different.
Such as, the evolutionary history of DNA methylation in gene bodies and transposons is
independent. Zemach et al. quantified DNA methylation in 17 eukaryotic genomes and found
that gene body methylation is an ancient property of eukaryotic genomes, and is conserved
between plants and animals, whereas selective methylation of transposons is not [9]. The
transposon methylation is only conserved in fungi [10], and appears to be related to the degree
of sexual outcrossing [11]. In general, the DNA methylation landscape can be either continuous
along the genome, or constituted by a series of heavily methylated DNA domains interspersed
with domains that are methylation free, and the methylation pattern is quite conserved [5].
3. Human methylomes
Because of its association with human development and disease, DNA methylation has stayed
in the research focus for almost half a century. The development of methods for whole-genome
methylation profiling has now enabled acquisition of the complete human methylomes,
especially powerful are methylome profiling techniques with single-base resolution sequenc‐
ing. Genome-wide, tissue-specific or cell type-specific DNA methylation profiling has begun
to shift the focus of DNA methylation research from mostly promoters and immediate
upstream enhancers to including intragenic regions and distal intergenetic regions [12]. These
revealed that methylation of gene bodies is more frequent than in promoters in the vertebrate
genomes [13]. Shen et al [14] characterized the methylome in purified peripheral blood
monocytes (PBMs) by using methylated DNA immunoprecipitation combined with high-
throughput sequencing, and found that promoters were commonly (58%) found to be
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unmethylated; whereas protein coding regions were largely (84%) methylated. Zilbauer et al
[15] provide detailed functional genome-wide methylome maps of five primary peripheral
blood leukocyte subsets including T-cells, B-cells, monocytes/ macrophages and neutrophils
obtained from healthy individuals and identified important cell-type specific hypomethylated
regions (HMRs) that strongly correlate with gene transcription levels. SNPs associated with
Figure 1. Methylation levels in 25 eukaryotic organisms. The organisms are organized according to their evolutionary
distance. Tree topology is determined from the NCBI Taxonomy (http://www.ncbi.nlm.nih.gov/guide/taxonomy/)
and displayed using TreeView X (http://darwin.zoology.gla.ac.uk/~rpage/treeviewx/index.html). The genome size is
indicated together with the percentage of methylated sites within three sequence contexts: CpG, CHG and CHH (H
being A, C or T).
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immune-mediated disease in genome-wide association studies (GWAS) preferentially
localised to these cell-specific regulatory HMRs, offering insight into the pathogenesis role of
DNA hypomethylation in regulating immune mediated disease. Recent insights into tissue-
specific intra-and intergenic methylation and into cancer methylomes suggest that both cancer-
associated DNA hypomethylation and hypermethylation are found throughout the genome
[16]. The hypermethylation includes promoters of tumor suppressor genes whose expression
becomes repressed, thereby facilitating cancer formation. Cancer-associated DNA hypome‐
thylation from intergenic enhancers, promoter regions, silencers, and chromatin boundary
elements may alter transcription rates. Whereas, the intragenic DNA hypomethylation might
modulate alternative promoter usage, production of intragenic noncoding RNA transcripts,
cotranscriptional splicing, and transcription initiation or elongation [16].The new discoveries
that genomic 5-hydroxymethylcytosine is an intermediate in DNA demethylation and exhibits
cancer-associated losses.
4. Methylomes in cell differentiation and reprogramming
During embryonic development, cells become gradually restricted in their developmental
potential and start elaborating lineage-specific transcriptional networks to ultimately acquire
a unique differentiated state [17].That is, cell differentiation is a process characterized by the
progressive loss of developmental potential and gain in functional specialization. During this
process, DNA methylation plays an important role in epigenetic programming by silencing
developmental genes and activating tissue-specific genes, thus establishing a cellular memory
that defines both cell lineage and cell type.
4.1. DNA methylation remodeling in the embryo development
Over the course of mammalian development, the genome undergo nearly complete remodel‐
ing of DNA methylation patterns. Primordial germ cells begin with very low DNA methylation
levels, then with gametogenesis parental imprinting tags are established, with substantially
methylated but differing methylomes in the sperm and egg. In the preimplantation early
embryo there is a wave of genome-wide demethylation that occurs, which is rapid in the
paternal genome, except for centromeric, repetitive and paternally imprinted genes, with a
comparative slow process occurring in the maternal genome [18].This is then followed by
heavy de novo methylation, DNA methylation patterns are then progressively re-established,
marking gradual commitment towards lineage-specific differentiation [19].
4.2. DNA methylomes in embryonic stem cells
Embryonic stem cells (ESCs) are a special population of pluripotent cells derived from the
inner cell mass (ICM) of a blastocyst during mammalian development. ESCs retain the ability
to indefinitely self-renew and differentiate into all cell types found in the adult body. The
importance of DNA methylation in ESC stemness maintenance and differentiation is indicated
by diverse studies demonstrating the following: (1) DNA methylation is essential for pluripo‐
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tency but not self-renewal in ESCs. Embryonic stem cells deficient in Dnmt1 and/or
Dnmt3a/3b or lacking CpG-binding proteins show a loss of pluripotency and severe impair‐
ment of differentiation potential, but still maintain self-renew [20-23]. (2) CpG methylation
contributes to differentiation of ESCs. In a search for differentially methylated (DM) regions
(DMRs) by reduced-representation bisulfite sequencing(RRBS), Meissner et al [24] found that
approximately 8% of CpGs that were unmethylated in ESCs became methylated in ESC-
derived neural progenitor cells and approximately 2% of CpGs methylated in ESCs were
unmethylated in the neural progenitor derivatives; Genomic analysis provides supporting
evidence for the CpG methylation of gene promoters to selectively silence differentiation genes
in ESCs, and global DNA demethylation is mostly linked with the upregulation of tissue-
specific genes [25]. (3) ESCs are enriched in non-CpG methylation. A recent major study using
Methyl-Seq technology reports significant non-CpG methylation in human ESCs, estimating
nearly 25% of total cytosine methylation to be non-CpG sites, with CHG and CHH as the major
motifs (where H=A, C, or T). Genomic regions enriched in non-CpG methylation are associated
with genes involved in RNA processing, RNA splicing and RNA metabolic processes.
Interestingly, enrichment of non-CpG methylation in gene bodies correlates with significantly
more intronic RNA.
4.3. DNA methylation remodeling in multipotent stem cells
Multipotent stem cells provide a unique intermediate between pluripotent ESCs and unipotent
differentiated cells. Multipotent stem cells also show significant reprogramming variability,
including somatic memory and aberrant reprogramming of DNA methylation [26].
4.3.1. Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are multipotent stem cells of mesodermal origin that can be
isolated from various sources and induced into different cell types [27]. Adipose tissue-derived
stem cells (ADSCs) are isolated from liposuction material, which provide an abundant source
of MSCs. Studies show that select adipogenic and nonadipogenic promoters in MSCs, ADSCs
and hESCs are hypomethylated and hypermethylated, respectively, suggesting DNA meth‐
ylation controls adipogenic differentiation by activating adipogenic-related genes and
silencing nonspecific lineage genes[27]. In addition, epigenomic changes in DNA methylation
and chromatin structure have been hypothesized to be critical in the determination of lineage-
specific differentiation and tumorigenesis of MSCs [27]. Leu et al [27] applied a targeted DNA
methylation method to methylate a polycomb group protein-governed gene, Trip10, in MSCs,
which accelerated the cell fate determination of MSCs. However, targeted methylation of HIC1
and RassF1A, both tumor suppressor genes, transformed MSCs into tumor stem cell-like cells.
4.3.2. Hematopoietic stem cells
Hematopoietic stem cells (HSCs) are a special population of multipotent stem cells that are
derived from the bone marrow and give rise to a subset of mature blood cells that directs
all  the  immune responses.  Accumulating evidence suggests  that  DNA methylation play
critical roles in the maintenance of both self-renewing hematopoietic stem cells and leukemic
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stem cells [29].  Changes in the DNA methylation profile have a critical  role in the divi‐
sion of these stem cells into the myeloid and lymphoid lineages and in the establishment
of a specific phenotype and functionality in each terminally differentiated cell  type [30].
HSCs  deficient  in  both  Dnmt3a  and  3b  show  a  loss  of  proliferative  ability  but  retain
differentiation potential,  suggesting de novo methylation is important for self-renewal in
HSCs  [28].  The  aberrant  DNA  methylation  has  been  associated  with  several  immune
deficiencies and autoimmune disorders [30].
4.3.3. Multipotent neural progenitor cells
The central nervous system (CNS) is composed of three major cell types-neurons, astrocytes,
and oligodendrocytes-which differentiate from common multipotent neural stem cells (NSCs).
Comparisons between ESCs, NSCs and terminally differentiated neurons demonstrate that the
majority of de novo methylated genes are already present in NSCs, suggesting that the bulk
of DNA methylation changes during differentiation is associated with a loss of pluripotency
and a commitment to a multipotent state, rather than terminal differentiation [28]. Interest‐
ingly, when NSCs further differentiate into astroglial lineage, selective promoter demethyla‐
tion occurs in glial marker genes, including GFAP and S100B [31, 32]. Loss of methylation using
5-azacytidine (5-azaC) also triggers premature glial differentiation [31]. Consistently, Dnmt1-
deficient NSCs precociously differentiate into astroglial cells, which have been linked to
increase JAK-STAT signaling and demethylation of the STAT1 and GFAP promoters [32].
4.4. DNA methylations in cell reprogramming
Epigenetic marks can be reset and usually result in the gain of developmental potential, called
epigenetic reprogramming. Researches indicated that mammalian somatic cells can be directly
reprogrammed into induced pluripotent stem cells (iPSCs) by introducing defined sets of
transcription factors Oct4, Sox2, Klf4 and c-Myc [33-35]. The ultimate aim of research on cell
reprogramming is to create iPSC that is identical to embryonic stem cells (ESC) and differen‐
tiates into tissue specific cell types with intact function, which will pave the way for great
advances in regenerative medicine in the future.
4.4.1. 5-hydroxymethylcytosine-mediated epigenetic modifications during reprogramming to
pluripotency
Although 5-hydroxymethylcytosine (5hmC) was discovered several decades ago, it became a
major focus of epigenomic research only after it was recently identified in murine brain and
stem cell DNA. 5hmC is an oxidative product of 5-methylcytosine (5mC) which catalyzed by
the ten eleven translocation (TET) family of enzymes [36]. TET1-mediated 5hmC modification
could contribute to the epigenetic variation of iPSCs reprogramming and iPSC-hESC differ‐
ences [37]. Wang et al [37] found that 5hmC levels is increased significantly during reprog‐
ramming to human iPSCs mainly owing to TET1 activation, and this hydroxymethylation
change is critical for optimal epigentic reprogramming, but does not compromise primed
pluripotency.
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4.4.2. Non-CpG cytosine methylation in cells reprogramming
Although methylation mainly occurs on the cytosines in the CpG dinucleotide context, non-
CG methylation (mCH:DNA methylation targeting CpA, CpT, and CpC dinucleotides) is
prevalent in brain, oocytes and pluripotent stem cell [38-40]. Compared to non-growing
oocytes (NGOs), germinal vesicle oocytes (GVOs) were over four times more methylated at
non-CG sites, indicating that non-CG methylation accumulates during oocyte growth.
Widespread methylome reconfiguration occurs during fetal to young adult development,
coincident with synaptogenesis. During this period, highly conserved non-CG methylation
(mCH) accumulates in neurons, but not glia, to become the dominant form of methylation in
the human neuronal genome[38]. Shirane et al [39] found that nearly two-thirds of all meth‐
ylcytosines occur in a non-CG context in GVOs. The distribution of non-CG methylation closely
resembled that of CG methylation throughout the genome and showed clear enrichment in
gene bodies. Ziller et al [40] reported a comprehensive analysis of non-CpG methylation in 76
genome-scale DNA methylation maps across pluripotent and differentiated human cell types,
and confirm non-CpG methylation to be predominantly present in pluripotent cell types and
observe a decrease upon differentiation and near complete absence in various somatic cell
types. Non-CpG cytosine methylation has been identified at a high level in stem cells and
reprogrammed progenitor cells, indicating that loss of this form of methylation may be critical
in the path from pluripotency to differentiation. The total level of global methylation and the
degree of non-CpG methylation is inversely proportional to the level of differentiation.
5. Methylomes in cancer
Carcinogenesis is a complex multifactorial process of the transformation of normal cells into
malignant cells, and is characterized by many biologically significant and interdependent
alterations triggered by the mutational and/or non-mutational (i.e., epigenetic) events. One of
these events, specific to all types of cancer, is alterations in DNA methylation. Aberrant DNA
methylation is frequently observed and considered to be a hallmark of cancers.
5.1. DNA methylome alterations induced by carcinogens
According to the mechanism of cancer causation, all carcinogenic agents may be divided into
genotoxic (carcinogenic agents that interact with DNA) and non-genotoxic (carcinogenic
agents causing tumor by mechanisms other than directly damaging DNA) carcinogens (Figure
2). Exposure to genotoxic carcinogens induces genotoxic and non-genotoxic effects in the DNA
methylome, whereas exposure to non-genotoxic carcinogens causes non-genotoxic effects
only. Genotoxic effects on the DNA methylome are consist of increased carcinogen–DNA-
adduct formation at methylated CpG sites and subsequent elevated mutation rates; however,
genotoxic effects may cause also non-genotoxic events in the DNA methylome by compro‐
mising ability of the DNA methylation machinery to methylate DNA accurately. Nongenotoxic
effects of both genotoxic and non-genotoxic carcinogens consist of global loss of DNA
methylation, gene-specific hypermethylation, and gene-specific hypomethylation. Non-
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genotoxic global DNA hypomethylation leads to genotoxic events such as elevated mutation
rates and genome instability. Gene specific DNA hypermethylation of critical tumor suppres‐
sor genes causes transcriptional repression and the loss of gene function. In contrast, gene
specific DNA hypomethylation induces activation of oncogenes and tumor-promoting genes.
Silencing of DNA repair genes, e.g., MGMT, BRCA1 and MLH1, or activation of xenobiotic
metabolizing genes, e.g., CYP1A1, may elevate mutation rates indirectly.
Figure 2. Alterations of the DNA methylome induced by carcinogens
5.1.1. Global DNA hypomethylation in cancer
DNA hypomethylation arises mainly from the loss of methylation at normally heavily
methylated areas of genome. The loss of global DNA methylation is one of the most common
DNA methylome alterations in human cancers, which is closely related to carcinogenesis. First,
genomic demethylation causes a significant elevation in mutation rates] and aberrant activa‐
tion of“normally”silenced tumor promoting genes [41-43]. Second, hypomethylation of DNA
results in the loss of genomic imprinting (LOI), which is currently considered as one of the
earliest and most frequent alterations in human tumors [44-46]. Third, demethylation of
repetitive sequences, such as long interspersed nucleotide elements (LINE)-1, short inter‐
spersed nucleotide elements (SINE), and retroviral intracisternal. Alu elements may cause
chromosomal abnormalities and genomic instability via the induction of permissive transcrip‐
tional activity of repetitive elements [47-48]. Finally, the recent research indicated that the loss
of 5hmC has been found in a broad spectrum of solid tumors, including lung, breast, brain,
gastric, and colorectal cancers [49-50].
5.1.2. Cancer-linked gene-specific DNA hypermethylation or hypomethylation
DNA hypermethylation is the most extensively studied epigenetic abnormality in cancer, and
the hypermethylation of promoter CpG islands causes permanent and stable transcriptional
silencing of a wide range of protein-coding genes and non-coding RNA genes. There is also
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growing evidence for the importance of non-CpG island-promoter methylation in cancer,
including methylation of CpG island shores [51], non-CpG promoters [52], and coding regions
[53], which results in gene silencing. A mechanistic link between DNA hypermethylation and
carcinogenesis is epigenetic silencing of critical tumor-suppressor genes, such as cyclin-
dependent kinase inhibitor 2A (CDKN2A; p16INK4A), secreted frizzled-related protein genes
(SFRPs), adenomatous polyposis coli (APC), Ras association (RalGDS/AF-6) domain family
member 1 (RASSF1A) [54], et al. It has been established unequivocally that role of epigeneti‐
cally-driven gene silencing has been the main mechanism favoring tumor development and
progression. This overshadowed the importance of gene-specific hypomethylation in cancer;
however, accumulating evidence indicates that the hypomethylation of “normally” methylat‐
ed CpG island-containing genes also plays a significant role in tumor development. Currently,
several hypomethylated tumor-promoting genes, including S100 calcium binding protein A4
(S100A4), plasminogen activator, urokinase (UPA), heparanase (HPA), synuclein, gamma
(SNCG), trefoil factor 3 (TFF3), and flap structure-specific endonuclease 1 (FEN1), have been
identified in major human cancers [55].
Anyway, cancer-linked gene-specific DNA hypermethylation and hypomethylation are
associated with the well-established hallmarks of cancer, including the acquisition of persistent
proliferative signaling, resistance to cell death, evasion of growth suppression, replicative
immortality, inflammation, deregulation of energy metabolism, induction of angiogenesis,
and activation of invasion, complement and enhance each other in the disruption of cellular
homeostasis favoring cancer development [56]. Next, as examples, the role of DNA methyla‐
tion alterations in carcinogenesis was demonstrated in chronic lymphocytic leukemia and
glioma.
5.2. Methylome in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most frequent leukemia of adults in western
countries. Next-generation sequencing of whole genomes, exomes and DNA methylomes in
CLL has provided the first comprehensive view of somatic mutations and methylation changes
in this disease. Here, we mainly elaborate the change of DNA methylomes in CLL.
5.2.1. Hypomethylation contributes to the genomic instability and oncogene activation in CLL
Two decades ago, high-pressure liquid chromatography (HPLC) analysis revealed the genome
DNA of CLL to be globally hypomethylated relative to healthy controls. The subsequent study
found that aberrant hypomethylation of repetitive sequences, such as ALU, LINE and SATα
leading to genomic instability may be a contributing factor in the increased propensity of TP53-
deleted/mutated cases to acquire CLL genomic alterations [57]. Recently, next-generation
sequencing of the DNA methylome has also noted gene body hypomethylation to be partic‐
ularly widespread within enhancer regions in CLL patients [57-59]. After the CLL genome was
discovered to be hypomethylated, hypomethylation of oncogene is found to correlate with
increased protein expression in CLL. Such as, BCL2, a key anti-apoptotic gene, MDR1, the
multiple drug resistance gene, and TCL1, an activator of NF-κB, were subsequently found to
be hypomethylated and upregulated in CLL [57].
Methylomes
http://dx.doi.org/10.5772/57535
157
5.2.2. Cells origin and subtypes of CLL on basis of genome and methylome
Because of the differences in the immunoglobulin heavy variation (IGHV) mutational status
and B-cell receptor reactivity, chronic lymphocytic leukemia was classified into two subtypes:
chronic lymphocytic leukemia lacking significant somatic IGHV mutation (uCLL) and chronic
lymphocytic leukemia with significant somatic IGHV mutation (mCLL), which was derived
from naive B cells and memory B cells [60]. Most mutated genes cluster in a few molecular
pathways that are also differentially represented in the two subtypes of CLL. Mutations in
NOTCH1 signaling, mRNA splicing, processing and transport, and DNA damage response
pathways are more common in uCLL, whereas mutations in the innate inflammatory pathway
occur predominantly in mCLL.
B cells at different maturation stages require a different level of DNA methylation reprogram‐
ming to give rise to uCLL and mCLL. Microarray analysis of a large series of patients indicates
that uCLLs acquire approximately seven times more DNA methylation changes than mCLL
compared with their respective cells of origin. In particular, two-thirds of the DNA methylation
changes that take place in the transformation of naive B cells into uCLL can also be detected
in their physiological differentiation into memory B cells [58].
By genome-wide differential DNA methylation profile analysis in uCLL and mCLL, CLL was
derived from three different B-cell subpopulations: uCLL resembles both native B cells (IgD
+and CD27-) and CD5+ pregerminal center mature B cells (CD5+, IgD+, and CD27-), whereas
mCLL is more similar to non class-switched and class-switched memory B cells (IgM/ D+ or
IgA/G+, CD27+). The third group of CLL was accompied with an intermediate DNA methyla‐
tion pattern and enriched for mCLLs with a significantly lower level of somatic IGHV
mutations [58]. This group might be derived from a third B-cell type, for example, an antigen-
experienced, germinal center-independent B cell that has acquired low levels of somatic
hypermutations [60].
5.3. Methylomes in glioma
Glioma is the most frequent and devastating primary brain tumor in adults. Aberrant DNA
methylation contributes to glioma development and progression.We employed MeDIP-chip
to investigate the whole-genome differential methylation patterns between glioma and normal
brain samples. We identified 524 hypermethylated and 114 hypomethylated differential
regions in the primary gliomas. Intriguingly, some of the human genome differential methyl‐
ation regions (DMRs), 199 hypermethylation and 30 hypomethylated differential regions were
mapped to genomic regions without any gene annotation (Fig 3A). Only 325 hypermethylation
and 74 hypomethylation differential regions were mapped to annotated genes regions,
including promoter, intragenic and downstream of genes (Fig3A). A great percentage of
DMRs, 63.0% (216) of hypermethylated and 79.0% (60) of hypomethylated differential regions,
was mapped to promoter regions of known genes (Fig 3B). 53 hypermethylated and 27
hypomethylated differential regions were mapped to the regions which were both promoter
of known genes and CpG islands (Fig 3C). Thus, we identified many novel DMRs that reside
in promoters, intragenic, downstream of known genes and unannotated genomic regions in
primary gliomas. Since change of promoter methylation status may have close related with
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gene expression and involved in tumor development, we focused on the analysis of DMRs in
glioma which were mapped to gene promoter regions. The 216 promoter hypermethylated
genes and 60 promoter hypomethylated genes identified by MeDIP-chip were analyzed
according to their chromosomal location and the physical distribution of these loci was further
analyzed (Fig 3D). Except that there were intensive promoter hypermethylation genes in 1, 2,
3, 17 and X chromosomes, the promoter hypermethylated genes were found to be distributed
evenly in other chromosomes. While promoter hypomethylated genes mainly distributed in
1, 11, 16, 19, 20 and 22 chromosomes, the number of genes in these chromosomes account for
the majority of the total promoter hypomethylated genes [61].
Figure 3. Genome-wide analysis of DMRs in primary glioma. (A) Number of differentially methylated regions that are
associated with or without genes. (B) Distribution of diifferentially methylated regions associated with genes. Most of
the identified DMRs associated with genes were mapped to gene promoters. (C) Number of DMRs which were both
gene promoters and CpG islands. (D) Chromosomal distribution of 216 promoter hypermethylated genes and 60 pro‐
moter hypomethylated genes.
6. The connected networks of DNA methylation, histone modifications,
transcript factor and miRNAs
Epigenetic mechanisms include: DNA methylation; histone tail modifications; chromatin
remodeling; and noncoding RNA expression. DNA methylation is essential for a properly
functioning genome through its roles in the maintenance of chromatin structure, chromosome
stability and transcription. Histones are the protein moiety around which DNA is packaged
within the chromatin, and they can suffer a variety of post-translational modifications of their
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N-terminal tails, including acetylation, methylation, phosphorylation, sumoylation, ubiquiti‐
nation and ADP ribosylation [62,63]. miRNAs are ~20–22 nucleotide non-coding RNA
molecules that tend to negatively regulate genes by binding to the 3' untranslated region of
the target mRNA via the RNA-induced silencing complex causing mRNA destabilization and/
or translational inhibition [64,65]. Growing evidence supports a role for miRNAs as both
targets and effectors in aberrant mechanisms of DNA methylation [66,67]. Meanwhile,
miRNAs are also invovlved in the control of DNA methylation by targeting the DNA meth‐
ylation machinery [68, 69]. In this section, we combined with our own work to demonstrate
the connected networks of DNA methylation, histone modifications, transcript factor and
miRNAs in glioma. On the basis DNA methylome of glioma, we identified fifteen new
methylated genes including 9 hypermethylated genes(ANKDD1A, GAD1, SIX3, SST,
PHOX2B, PCDHA8,PCDHA13, HIST1H3E and LRRC4) and 6 hypomethylated genes (F10,
POTEH, CPEB1, LMO3, ELFN2 and PRDM16) were validated by the Sequenom MassARRAY
platform and bisulfite sequencing (BSP) in glioma. Aberrant promoter methylation and
changed histone modifications were associated with gene abnormal expression in glioma.
miR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation [61],
however, miR-101 regulates histone methylation modication of hypomethylated gene CPEB1
by targeting EZH2 and EED, and DNMT3A, and affected their methylation level and expres‐
sion in glioma [70].
6.1. The regulation networks between hypermethylated gene, miRNA, transcript factor and
target gene in glioma
Leucine-rich repeat C4 (LRRC4) gene, a new hypermethylated gene identified by DNA
methylome of glioma, are highly specific to brain tissue and it behaved as a tumor suppressor
gene in the pathogenesis of gliomas. Methylation of the LRRC4 promoter has been considered
as one of the important mechanisms inactivating LRRC4 in gliomas. Exogenous overexpres‐
sion of LRRC4 could inhibit glioma cells growth and arrest glioma cells in the G0/G1 phase of
the cell cycle. Induction of LRRC4 expression inhibited glioma cell proliferation and invasion
by downregulating the ERK/MAPK and PI-3K/AKT signaling pathways [71-75].
6.1.1. LRRC4-AP-2-miR-182-LRRC4 loop played important role in the pathogenesis of glioma
It’s known that miRNAs took part in proliferation and growth in glioma cells. miR-182 or
miR-381 overexpression could promote glioma cell growth in vivo and in vitro. Therefore, they
were considered to be potential therapeutic biomarker in glioma. miR-182 or miR-381 silencing
could arrest glioma cells in the G0/G1 phase of the cell cycle and inhibit glioma cells growth
by upregulating phosphorylated Rb and suppressing E2F3. LRRC4 was the co-target gene of
miR-182 and miR-381. The expression of miR-182, miR-381 and BRD7 were inversely correlated
with LRRC4 expression in gliomas. miR-182 and miR-381 silencing was found to inhibit the
expression of BRD7, upregulate phosphorylated Rb, suppress E2F3, arrest glioma cells in the
G0/G1 phase of the cell cycle, inhibit glioma cells growth and induce differentiation of glioma
cells to astrocyte-like cell by upregulating LRRC4 and suppressing LRRC4-mediated binding
of AP-2/SP1/E2F6/c-Myc to BRD7 in ERK/MAPK and PI-3K/AKT signal pathways [76].
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Transcription of miR-182 was induced by transcription factor AP-2 predicted by online
softwares and confimed by ChIP. According to our previous results, miR-182 was verified to
inhibit the expression of LRRC4, and LRRC4 might inhibit the expression and transcription of
AP-2 through negatively regulating the ERK/MAPK and PI-3K/AKT signaling pathways. It’s
indicated that the LRRC4-AP-2-miR-182-LRRC4 loop formed among LRRC4, miR-182 and
AP-2 was involved in glioma development [77].
6.1.2. LRRC4-miR-185/SP1-DNMT1-LRRC4 loop played an important role in glioma
miR-185 could function as a tumor suppressor gene. It’s certified that miR-185 could inhibit
glioma cell growth, motility and invasion identified by MTT, scratch test and transwell test
[78-80]. DNMT1 is one of the most important DNA methyltransferase which maintains
methylation. Our research showed that overexpression of miR-185 could inhibit DNMT1 and
reduce global methylation by HPLC-DAD, and decreased the expression of nine new hyper‐
methylated genes (LRRC4, ANKDD1A, GAD1, HIST1H3E, PCDHA8, PCDHA13, PHOX2B,
SIX3 and SST) [61]. Hence, miR-185 was considered to inhibit glioma cells growth and
migration by targeting DNMT1, reducing global methylation and recovering expression of
such hypermethylation genes as LRRC4.
miR-185 also was predicted to participate in Rho GTPase activity based on GO analysis, while
CDC42 and RhoA were the main elements regulating Rho GTPase. Then CDC42 and RhoA
were identified to be the direct targets of miR-185[61]. Further, CDC42 and RhoA were
inversely correlated with miR-185 expression in gliomas. miR-185 was clarified to mediate
glioma cell growth and migration by inhibiting CDC42 and RhoA and VEGFA indirectly [61].
It’s verified that overexpressing LRRC4 could increase the expression of miR-185, while
miR-185 could regulate global methylation by inhibiting DNA methyltranferase DNMT1 and
increasing the expression of such hypermethylation gene as LRRC4. There may be form
LRRC4-miR-185-DNMT1-LRRC4 loop which LRRC4 are to be as core the loop, miR185 and
DNMT1 that participating in glioma development. In addition, DNMT1 was positively
regulated by SP1, and it could increase the expression of LRRC4, while LRRC4 could also
inhibit SP1 by negatively regulate ERK/MAPK and PI-3K/AKT signal pathway. So that the
LRRC4-SP1-DNMT1-LRRC4 loop formed among LRRC4, SP1 and DNMT1 took part in the
glioma formation.
In conclusion, development of glioma is the pathological processing with multiple genes and
multi-stages. Genes, miRNAs and DNA methylation play an important role in glioma
formation. They may support or antagonize each other and construct complicated network in
glioma. In sum of above study, at the time of LRRC4 regulating miRNAs as a tumor suppressor,
those miRNAs regulated by LRRC4 were found to regulate the binding of transcription factors
to DNA in their targets mediated signaling pathways by directly targeting genes (such as
LRRC4), or regulate methylation and expression of such hypermethylation genes as LRRC4
by directly targeting DNA methyltransferase and controlling global methylation. And
multipases regulation loops which the core was LRRC4 were formed. They were LRRC4-AP-2-
miR-182-LRRC4, LRRC4-miR-185-DNMT1-LRRC4 and LRRC4-SP1-DNMT1-LRRC4. These
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loops participated in glioma development with multiple positive feedback formation among
them (Fig 4).
Figure 4. The regulation networks of hypermethylated genes, miRNA, DNMT, transcript factors and targets genes in
glioma
6.2. miR-101 regulates the expression of hypomethylated/hpermethylated genes by
different histone protein methylaiton modification
It’s well-known that miRNAs play significant role by regulating gene expression in tumors.
We assumed to analyze the upregulation mechanism of hypomethylation genes in the extent
of gene regulation by miRNA. Subsequently, we predicted miRNAs which could regulate
hypomethylation genes CPEB1. Interestedly, CPEB1was predicted to be a target of miR-101
by online software Targetscan6.0. It’s confirmed that miR-101 could bind to the 3’UTR of
CPEB1 and inhibit their expression [70].
6.2.1. miR-101 indirectly suppressed expression of CPEB1 and affected their methylation levels by
targeting EZH2, EED and DNMT3A and regulating histone methylation in glioma cells
As miR-101 regulated the methylation status and expression of gene through histone modifi‐
cation, it may regulate the methylation status of CPEB1 in the same way. Hence, the effect of
miR-101, EZH2 siRNA, EED siRNA and DNMT3A siRNA on histone methylation and
expression of CPEB1 was detected. ChIP combining with qRT-PCR and BSP was used to verify
that miR-101 decreased the H3K4me2 and H3K27me3 occupancy at CPEB1 core promoter and
increased the H3K9me3 and H4K20me3 occupancy at CPEB1 core promoter by targeting
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EZH2, EED and DNMT3A, then it recovered the methylation levels of CPEB1 gene promoter,
and indirectly down-regulating the expression of these hypomethylation genes.
6.2.2. miR-101 recovered the expression of hypermethylation gene LRRC4 by down-regulating
H3K27me3 occupancy and hypomethylation level of LRRC4 in glioma cells
LRRC4 has  been a  glioma suppressor  gene and its  hypermethylation and down-expres‐
sion is common in glioma. In order to clarify the mechanism of LRRC4 regulation, miRNAs
regulating  LRRC4  were  predicted.  miR-101  was  predicted  to  target  LRRC4.  Here,  we
indicated that miR-101 could not bind to 3’UTR of LRRC4, but it remain to upregulate the
expression of LRRC4 in glioma cells.  miR-101 decreased the occupancy of H3K27me3 at
LRRC4 core promoter and induced hypomethylation of LRRC4 by targeting EZH2, EED
and DNMT3A [81].
Token together, deregulation of gene methylation including hypermethylation and hypome‐
thylation plays an important role in carcinogenesis of glioma. Hypermethylation or hypome‐
thylation of genes and their deregulated expression could be applied to predict the early
diagnosis and prognosis of glioma. miRNAs are small noncoding RNA, around 22-24 nucleo‐
tides in size. They could not only directly regulate expression hyper/hypo-methylation genes
by binding to 3’-UTR of genes, but also regulate the methylation level and gene expression
through histone and DNA methylation modification by targeting histone and DNA methyl‐
transferases (Fig 5).
Figure 5. The regulation networks of miRNA, genes methylation and histone protein modification in glioma
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7. Conclusion
The advances in next-generation sequencing technologies have allowed for mapping of DNA
methylation and its derivatives: 5hmC and 5fC at base-pair resolution. These studies have
provided key new insights into the function, dynamics and distribution of DNA methylation
in vertebrate genomes. In the near future, studies of DM sites and focal DMRs will aid the
discovery of transcription factors and transcription regulatory elements involved in control‐
ling the expression of specific genes in vivo. More experiments in model systems will be done
to directly test the functionality of DMRs or individual DM sites identified in epigenomic
profiles. It is likely that intragenic and distant intergenic changes in DNA methylation will be
studied much more than at present for their contribution to diseases involving epigenetic
deregulation, especially cancer, immunological diseases and neurological diseases.
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